Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02424708 · ClinicalTrials.gov registry record · Phase 2
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
A Phase 2 study, sponsored by Bastyr University.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02424708: Completed Phase 2 study, sponsored by Bastyr University.
NCT02424708 is a Phase 2 study that has completed, run by Bastyr University. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02424708, a Phase 2 study, has completed, sponsored by Bastyr University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Glutathione is an important nutrient for brain function and loss of glutathione has been implicated in Parkinson's disease. Glutathione is an antioxidant made in the body out of three amino acids, the nutrients that make up protein. This study will determine whether administration of either dose of glutathione, as a nasal spray, improves PD symptoms over time in a population of individuals with Parkinson's disease (PD).
Interventions
- DRUG Placebo
- DRUG Reduced Glutathione 100mg
- DRUG Reduced Glutathione 200mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
What the finished NCT02424708 record still lists
NCT02424708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02424708 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02424708 about?
NCT02424708 is a clinical study titled "Phase IIb Study of Intranasal Glutathione in Parkinson's Disease". Glutathione is an important nutrient for brain function and loss of glutathione has been implicated in Parkinson's disease. Glutathione is an antioxidant made in the body out of three amino acids, the nutrients that make up protein. This study will determine whether administration of either dose of ...
What is the current status of trial NCT02424708?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2015-04. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02424708?
The interventions under investigation include: Placebo (DRUG), Reduced Glutathione 100mg (DRUG), Reduced Glutathione 200mg (DRUG).
Who is sponsoring clinical trial NCT02424708?
This trial is sponsored by Bastyr University, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02424708's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia